To add to my post about NP Aerospace, here is this part from Tuesdays Press Release.
Other proprietary technologies include the manufacture of high performance, lower cost ballistic materials for opaque armor applications at its subsidiary, SINTX Armor. SINTX Armor is expected to begin production of a competitively priced body- and vehicle-protective armor product that has undergone successful testing.
This was likely what Sintx and NP Aerospace have been waiting for in regards to some sort of announcement between the two.
========================================
To your so called deflections Joe, my last post specifically indicated that i participated in shareholder rights offering and ive said as much since the 2022 offering. To do so i had to be a shareholder already. I added it after posting that post during the 15min edit window and added it to the wrong paragraph; maybe you just missed it.
Participating in shareholder rights offerings is one way and what i have done.
One thing that would help Sintx/SINT proper valuation is an end to the short and distort campaign thats been waged here for 9 years. It is a fact that there has been extensive shorting and distorting here. Its insanely obvious between the 2022 RS and the 2023 RS with the extent of naked shorting. Every offering over that time included known shorting and distorting fund Anson Group with its family of funds coupled with 50% price declines before and after the offerings. These facts, detailed below.
Another thing that would help with Sintx valuation is management & other Sintx employees finally buying shares after a new shareholder plan is voted on this year. They deserve to reap the rewards of their labor when all those products begin to see the light of day. That coupled with major tutes taking positions. Then for the price to really take off, finally the public announcement of Sintx partnership with Zimmer Biomet as well as partnerships with Solventum & Cardinal Health all with some degree of guidance as to when these strategic partnerships will bring products in the Ortho, PPE, & Catheter industries to market. A sale of Armor division or NP Aerospace partnership certainly wouldnt hurt!
As Sonny is a medical and material research scientist, new CEO to help guide Sintx through all that is a good idea. So him stepping down is the right move if this is going to play out something like i just laid out.
This post shows how this group of funds work together to short offerings and buy them so to circumvent rule 17 CFR § 242.105a - Short selling in connection with a public offering. That said, they do appear to be violating the rules on trading material non-public information. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174599544
I go into some of the evidence of this in the February 2023 offering where they drove the price up & naked shorted it down. Ansons family of funds participated in every offering in 2023 up to the recent RS. Anson and the other funds its associated with are known for their short and distort actvity and are under investigation by the DOJ. SEC slapped it with a ticket fine basically that will in no way discourage its shorting and distorting methods. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602472
Look at this dated chart and you can see that SINT had been trading in a downward channel but in 2022 price manipulation went to a new level with 50% drops in price before and after each offering. All the while Sintx revenue has been growing as well as its list of collaborations with the military and in the aerospace markets. https://i.imgur.com/xMRDE8n.jpeg